BIOC stock is moving higher in pre-market trading on January 8, 2020, after the company announced it was awarded a patent.
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular offerings designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has been awarded U.S. Patent No. 10,527,611 titled, DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS from the United States Patent and Trademarks Office (USPTO). The newly issued patent covers devices for the detection of cells of interest, including circulating tumor cells (CTCs), that are shed into the bloodstream by solid tumors where an antibody, or mixture of antibodies, and any solid surface are used for cell capture, detection, and analysis. This patent includes any biological sample type of interest and includes the use of single antibodies or cocktails of antibodies.
“The granting of this patent broadly expands Biocept’s intellectual property estate for capturing and detecting cells of interest using antibodies, which combines nicely with our patented microchannel and cell staining platforms,” said Lyle Arnold, Ph.D., Biocept’s Chief Scientific Officer. “This allowed patent also interfaces very well with our other patented technologies that include a blood collect tube, and ctDNA analysis platforms for aiding patient treatment decisions.”
The device claims covered by this issued patent broadly cover the use of antibodies for the capture and detection of target cells of interest on any solid surface. This includes CTCs, as well as any other cell of interest. Combined with the company’s patented microchannel and cell staining platform technologies, Biocept now has patented the capability to enable the capture of any cell of interest, including very rare cells, that may be present in blood and any other biological sample type.
Michael Nall, Biocept’s President and CEO, added, “We continue to lead the way in innovation for liquid biopsy technology, and this latest patent demonstrates our leadership in creating new methodologies to identify potential cancer cells, or cells of any type for that matter. We are very proud of our innovations in the industry and look forward to sharing future applications for this patented technology to capture cellular targets in biological fluids, even when found in very small quantities.”
To get these stocks much faster (real-time) with alerts, check out the tool we use here. There’s nothing like it on the market.